Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513878/
https://www.ncbi.nlm.nih.gov/pubmed/28744140
http://dx.doi.org/10.2147/OTT.S122397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513878/
https://www.ncbi.nlm.nih.gov/pubmed/28744140
http://dx.doi.org/10.2147/OTT.S122397

Ejemplares similares